{"filings":[{"id":1009279,"accession_number":"0001690585-26-000029","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-06-12T11:00:32+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dianthus posts corporate presentation with Phase 3 CAPTIVATE interim data for claseprubart in CIDP","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Interim responder analysis data for first 40 patients from Part A of Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy.","Presentation posted on investor relations website on June 11, 2026.","No specific numeric results disclosed in the filing text; actual data is in the presentation slides."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609516,"accession_number":"0001690585-26-000026","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-05-22T20:10:16+00:00","items":["5.07"],"status":"ready","headline":"Dianthus stockholders elect directors, approve say-on-pay, ratify Deloitte at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sujay Kango, Anne McGeorge, and Jonathan Violin elected Class II directors with 42.7M, 34.8M, and 42.8M votes for, respectively.","Advisory vote on executive compensation passed: 41.0M for, 1.7M against, 0.5M abstain, 3.6M broker non-votes.","Ratification of Deloitte & Touche as auditor for 2026 approved: 46.3M for, 5.3K against, 0.5M abstain, no broker non-votes.","All three proposals passed with substantial majorities; no material changes to governance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94715,"accession_number":"0001690585-26-000021","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.","Cash $1.2B at March 31, including $719M gross from March public offering; runway into 2030.","Claseprubart: Early GO in CAPTIVATE CIDP trial; Phase 3 gMG trial mid-2026 with top-line 2H'28.","DNTH212: Priority indications SjD, SLE, DM; Phase 1 healthy volunteer data expected 2H'26.","Orphan Drug Designation for claseprubart in MG; FDA agreed to remove ANA screening and DIL reclassification."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107303,"accession_number":"0001690585-26-000010","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA agrees to remove ANA screening, reclassify lupus risk for Dianthus' claseprubart trials","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA agreed to remove anti-nuclear antibodies (ANAs) as screening criteria for all ongoing and future claseprubart trials.","Routine ANA testing during claseprubart trials will be eliminated per FDA feedback.","Hypothetical risk reclassified from systemic lupus erythematosus (SLE) to drug-induced lupus (DIL), a reversible side effect.","No cases of SLE or DIL have been observed in any claseprubart program to date.","Company posted an updated corporate presentation on its website summarizing these changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107302,"accession_number":"0001193125-26-103053","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dianthus Therapeutics raises ~$673.5M in public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,313,582 shares at $81.00/share and pre-funded warrants for 402,468 shares at $80.999/share.","Underwriters exercised in full option to purchase additional 1,157,407 shares on March 11, 2026.","Net proceeds expected to be approximately $673.5 million after underwriting discounts and expenses.","Offering expected to close March 12, 2026; securities offered under shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107301,"accession_number":"0001193125-26-097555","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.","Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).","FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.","Cash $514.4M provides runway into 2028.","Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107300,"accession_number":"0001193125-26-009898","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dianthus expects ~$514M cash at year-end 2025; CEO to present at JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents, and short-term investments of ~$514M as of Dec 31, 2025.","Actual results may differ materially due to completion of financial closing procedures.","CEO Marino Garcia to present at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.","Presentation focuses on advancing the autoimmune-focused pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123660,"accession_number":"0001193125-25-266867","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus reports Q3 net loss $36.8M; gMG Ph2 data positive, CIDP Ph3 interim accelerated to Q2'26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $36.8M ($0.97/share) vs $25.2M ($0.74/share) Q3'24; R&D $32.5M on higher clinical costs.","Phase 2 MaGic trial of claseprubart in gMG met endpoints with stat sig MG-ADL and QMG improvements at Week 13.","CIDP Phase 3 CAPTIVATE trial interim responder analysis accelerated to Q2'26 (from 2H'26) due to faster enrollment.","In-licensed DNTH212 (bifunctional BDCA2/BAFF-APRIL inhibitor) from Leads Biolabs; Ph1 healthy volunteer data expected 2H'26.","Adjusted cash ~$525M after $30M DNTH212 milestone payments; runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":1752000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123659,"accession_number":"0001193125-25-262188","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dianthus Therapeutics posts updated corporate presentation; no specific material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on company's investor relations website on November 3, 2025.","Presentation filed as Exhibit 99.1 to the 8-K; detailed content not available in the excerpt provided.","No financial results, pipeline updates, or guidance changes are included in the filing text.","Routine update; no material new operational or strategic information identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123658,"accession_number":"0001193125-25-240858","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).","Additional up to $962M in development, regulatory, and sales-based milestones across five indications.","Tiered royalties from mid-single digits to low double-digit on ex-Greater China net sales.","Preliminary cash $555M as of Sep 30, 2025; pro forma $525M after $30M payment to Leads."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140345,"accession_number":"0001193125-25-200715","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dianthus raises ~$270M in public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 6,487,879 common shares at $33.00/share and 1,112,121 pre-funded warrants at $32.999/share.","Underwriters exercised in full option for additional 1,140,000 shares.","Net proceeds expected to be approximately $270 million after discounts and expenses.","Offering priced Sept 9, 2025; closing expected Sept 11, 2025.","Pre-funded warrants exercisable at any time; beneficial ownership cap of 4.99%-19.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140344,"accession_number":"0001193125-25-197751","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Dianthus reports positive Phase 2 MaGic trial for claseprubart in gMG; both doses meet endpoints","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Claseprubart 300mg Q2W: MG-ADL mean change -4.6 (placebo-adjusted -1.8, p=0.0113); QMG -4.4 (adj. -2.4, p=0.0144) at Week 13.","Claseprubart 600mg Q2W: MG-ADL mean change -5.4 (adj. -2.6, p=0.0006); QMG -4.5 (adj. -2.5, p=0.0111).","Rapid onset: both doses showed stat. significant MG-ADL and QMG improvement as early as Week 1.","Favorable safety: no related serious infections, SAEs, or discontinuations; no Boxed Warning or REMS anticipated for planned autoinjector.","Phase 3 gMG trial evaluating 300mg Q2W and Q4W vs placebo planned to start in 2026; CIDP and MMN data expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140343,"accession_number":"0000950170-25-105002","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus Q2 net loss $31.6M ($0.88/sh); cash $309.1M; gMG Ph2 data due Sept","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $309.1M as of June 30, 2025; runway into 2H 2027.","Net loss $31.6M ($0.88 basic/diluted EPS) vs $17.6M ($0.51) in Q2 2024.","R&D expenses $26.3M (incl. $2.5M stock-based) vs $18.1M; increase driven by Phase 2/3 costs.","Top-line Phase 2 MaGic trial results for claseprubart in gMG anticipated September 2025.","Phase 3 CAPTIVATE CIDP trial on track; interim responder analysis expected 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":1356000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157989,"accession_number":"0000950170-25-076304","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Dianthus director Moulder resigns; Read appointed as Class III director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leon O. Moulder, Jr. resigned from Board effective May 22, 2025, with no disagreement.","Board appointed Simon Read, Ph.D. as Class III director and to S&T and N&CG Committees.","Dr. Read receives initial option for 25,000 shares vesting over 3 years; cash compensation of $40k/yr plus $5k per committee.","Annual meeting elected Garcia and Soteropoulos as Class I directors; advisory vote approved exec compensation; Deloitte ratified as auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157988,"accession_number":"0000950170-25-069195","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus Q1 net loss $29.5M; gMG trial enrollment complete, top-line Sep 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.5M ($0.82/sh) vs $13.7M ($0.54/sh) Q1 2024; cash $331.5M, runway into 2H'27.","Phase 2 MaGic gMG trial enrolled 65 patients; top-line results expected September 2025.","Phase 3 CAPTIVATE CIDP trial ongoing; interim responder analysis 2H'26.","Phase 2 MoMeNtum MMN trial ongoing; top-line results 2H'26.","Appointed John C. King as CCO and Sujay Kango to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1163000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176381,"accession_number":"0000950170-25-037125","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus reports FY2024 net loss $85M; Phase 2 gMG top-line on track for 2H'25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $85.0M ($2.55 per share) in FY2024, vs $43.6M ($8.45 per share) in FY2023.","Cash, cash equivalents and investments of $357.0M as of Dec 31, 2024, providing runway into 2H'27.","R&D expenses rose to $83.1M from $32.8M, driven by clinical and CMC costs for DNTH103.","Phase 2 MaGic gMG trial on track for top-line results in 2H'25; Phase 3 CIDP interim analysis in 2H'26.","Appointed John C. King as CCO and Sujay Kango to Board on March 5, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176380,"accession_number":"0000950170-25-033075","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Tomas Kiselak resigns; Sujay Kango appointed to board and compensation committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tomas Kiselak resigned from Dianthus Therapeutics board effective March 4, 2025; no disagreement cited.","Sujay Kango appointed as Class II director and member of Compensation Committee, effective March 4, 2025.","Kango receives initial option grant of 25,000 shares vesting over three years; cash compensation of $40,000/yr (board) and $6,000/yr (committee).","Kango will enter into a standard indemnification agreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193239,"accession_number":"0000950170-24-135775","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dianthus Therapeutics posts updated corporate presentation; no specific financial or operational news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed under Item 8.01; presentation posted on IR section of website dated December 2024.","No new financial results, guidance, or material events are provided in the filing text.","The exhibit (Ex-99.1) is a corporate presentation slide deck, but its content is not summarized in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193238,"accession_number":"0000950170-24-123255","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus Therapeutics Q3 net loss $25.2M; cash $342.6M; Phase 3 CIDP trial planned by YE 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.2M ($0.74/sh) vs $14.8M ($3.78/sh) in Q3 2023; R&D expense rose to $25.5M from $8.0M.","Cash, equivalents and investments $342.6M as of Sept 30, 2024; projected runway into 2H 2027.","Initiation of pivotal Phase 3 CIDP trial (single, two-part, randomized withdrawal) expected by year-end 2024.","Phase 2 MaGic gMG trial on track for top-line data 2H 2025; Phase 2 MoMeNtum MMN trial for 2H 2026.","Steven Romano, M.D., appointed to board effective Sept 16, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":4909000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209605,"accession_number":"0000950170-24-106820","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dianthus Therapeutics appoints Steven Romano, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Steven Romano, M.D. as Class III director and member of Science & Technology Committee, effective September 16, 2024.","Initial option grant of 22,000 shares vesting one-third annually over three years.","Annual cash compensation: $40,000 for board service plus $5,000 for S&T Committee, paid quarterly.","Dr. Romano will also be eligible for future annual equity grants under the Non-Employee Director Compensation Policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209604,"accession_number":"0000950170-24-093920","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus reports Q2 net loss $17.6M; cash $360.7M funds pipeline into 2H'27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.6M ($0.51/share) vs $11.1M ($12.73/share) in Q2 2023.","Cash, equivalents & short-term investments $360.7M as of June 30, 2024, projected runway into 2H'27.","Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H'25.","IND cleared for Phase 2 MoMeNtum trial in MMN; top-line results anticipated 2H'26.","Alison Lawton appointed Chair of Board, effective July 1, 2024, succeeding Lonnie Moulder."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":2737000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227706,"accession_number":"0000950170-24-069675","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dianthus Therapeutics presents updated corporate deck at Jefferies Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation disclosed on June 6, 2024.","CEO Marino Garcia presented the deck at Jefferies Global Healthcare Conference on the same date.","No specific financial or pipeline updates provided in the filing or exhibit text.","Presentation is furnished under Item 7.01 and not filed for SEC liability purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227705,"accession_number":"0000950170-24-065371","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.07","5.02","9.01"],"status":"ready","headline":"Dianthus shareholders approve 2.93M share increase to stock option plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved an amendment increasing shares reserved under the stock option plan by 2,931,820 shares.","Evergreen provision raised from 4% to 5% of outstanding shares annually through 2028; plan expiration extended to March 14, 2034.","Class III directors Leon O. Moulder Jr. and Alison F. Lawton elected; advisory votes on executive compensation approved with 23.0M votes for, 26.8K against.","Stockholders ratified Deloitte as independent auditor for FY2024 with 24.1M votes for.","Advisory vote on executive compensation frequency set to every year based on 23.0M votes for one-year interval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227704,"accession_number":"0000950170-24-056925","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus Therapeutics Q1 net loss $13.7M; cash $377M funds into 2H 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M ($0.54/share) vs $7.1M ($8.10/share) in Q1 2023.","Cash, equivalents, short-term investments $377M post $230M Jan 2024 PIPE.","Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H 2025.","MMN Phase 2 trial to start Q2 2024; CIDP Phase 2 trial in 2H 2024.","R&D expense $13.1M (incl. $0.8M SBC); G&A $5.6M (incl. $1.2M SBC)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":874000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246519,"accession_number":"0000950170-24-034667","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus reports FY2023 net loss $43.6M, cash $389M; Phase 2 gMG trial initiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 net loss $43.6M ($8.45/share), R&D $32.8M, G&A $18.2M.","Pro forma cash $389M (including $216M net from Jan 2024 PIPE); runway to 2H 2027.","Phase 2 MaGic gMG trial initiated Feb 2024; top-line data expected 2H 2025.","Phase 2 trials planned: MMN (Q2 2024) and CIDP (2H 2024).","Jeffrey Stavenhagen appointed CSO in Nov 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246518,"accession_number":"0001193125-24-011681","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Dianthus Therapeutics raises $230M in PIPE financing at $12.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE gross proceeds ~$230M from 14.5M common shares at $12.00 and 4.7M pre-funded warrants at $11.999.","New and existing investors participating: Bain Capital Life Sciences, RA Capital, Avidity Partners, and others.","Closing expected Jan 24, 2024; proceeds for R&D, working capital, and potential business development.","Placement agents: Jefferies, Evercore ISI, Stifel, Guggenheim Securities, Raymond James."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246517,"accession_number":"0000950170-24-002707","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Dianthus expects ~$173M cash at year-end 2023; to present at JPM conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents, and short-term investments of ~$173M as of Dec 31, 2023.","Audited FY2023 financials not yet available; actual results may differ materially.","CEO Marino Garcia to present at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263935,"accession_number":"0001193125-23-301206","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dianthus recasts audited financials for legacy OpCo; net loss $28.5M in 2022, going concern noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $28.5M in 2022, $13.1M in 2021; accumulated deficit $45.9M at Dec 31, 2022.","Revenue from related party Zenas $6.4M in 2022, $1.5M in 2021; R&D expense $29.4M.","Cash and investments $75.5M; going concern doubt due to insufficient capital for 12 months.","Merger with Magenta closed Sep 11, 2023, accounted as reverse recapitalization; all historical shares restated at 0.2181 exchange ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263934,"accession_number":"0000950170-23-062034","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dianthus reports Q3 net loss $14.8M; positive Phase 1 data for DNTH103, cash $189.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.8M ($3.78 per share); R&D expenses $8.0M, G&A $8.7M including $4.0M severance.","Cash, equivalents, and investments $189.9M at Sept. 30, 2023; runway into Q2 2026.","Phase 1 data: ~60-day half-life, potent classical complement inhibition, no serious adverse events.","Plan to start Phase 2 trials: gMG in Q1 2024, followed by MMN (1H24) and CIDP (2H24).","Completed merger with Magenta Therapeutics and $72M private placement led by Fidelity and others."],"consensus_eps_estimate":null,"consensus_eps_actual":-17.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":2369000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263933,"accession_number":"0000950170-23-055193","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Dianthus Therapeutics appoints Deloitte & Touche as new independent auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Deloitte & Touche LLP appointed as independent registered public accounting firm effective October 19, 2023.","No disagreements, reportable events, or prior consultations with Deloitte regarding accounting principles.","Appointment follows completion of merger with Dianthus Therapeutics OpCo, Inc. in September 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281158,"accession_number":"0001193125-23-238850","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K/A","filed_at":"2023-09-21T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"Dianthus files OpCo historical financials; pro forma cash runway into Q2 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["OpCo net losses: $18.2M (H1 2023), $28.5M (FY2022), $13.1M (FY2021).","Pro forma combined cash sufficient to fund operations into Q2 2026 per risk factors.","Board classified: Class I (2025 AGM), Class II (2026 AGM), Class III (2024 AGM).","Shares outstanding as of 9/21/2023: 14,813,295.","Material weakness identified in internal control over financial reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281159,"accession_number":"0001193125-23-233448","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-09-12T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","4.01","5.01","5.02","5.03","5.05","7.01","8.01","9.01"],"status":"ready","headline":"Reverse merger closed: Magenta becomes Dianthus Therapeutics; ticker changes to DNTH","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed: Magenta combined with Dianthus OpCo; new entity trades as DNTH; ~14.8M shares post-merger.","OpCo shareholders own ~77% of combined company; Magenta holders get ~23% plus CVRs for potential milestone payments.","Reverse stock split 1:16 effective pre-merger; prior Magenta share count reduced to ~3.8M.","New CEO Marino Garcia (ex-OpCo CEO); board reconstituted with 6 OpCo directors; auditor changed to Deloitte.","OpCo pre-closing financing raised ~$72M through sale of common stock and pre-funded warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281160,"accession_number":"0001193125-23-231669","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Magenta Therapeutics stockholders approve merger with Dianthus; closing expected Sept 11","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders approved share issuance and change of control (30.1M For, 6.3M Against) and reverse stock split (47.4M For).","Reverse stock split ratio range 1:10 to 1:18; final ratio determined by mutual board agreement.","Officer exculpation amendment not approved (30.0M For, 3.4M Against, 2.98M Abstentions).","Merger closing expected on or around Sept 11, 2023; post-closing co. to operate as Dianthus Therapeutics (DNTH).","Three Class II directors elected: Jeffrey Albers, Anne McGeorge, David Scadden."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299906,"accession_number":"0001193125-23-149353","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Magenta Therapeutics CSO Dr. Lisa Olson departs effective May 15, 2023 amid proposed merger with Dianthus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lisa Olson, Head of Research and CSO, left Magenta on May 15, 2023 due to completion of certain asset sales and announced proposed merger with Dianthus.","Magenta entered into a consulting agreement with Dr. Olson for work on an as-requested basis at an hourly rate.","Dr. Olson is eligible for severance benefits under her amended employment agreement, subject to execution of a separation agreement.","The departure is part of restructuring related to the proposed merger with Dianthus Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299905,"accession_number":"0001193125-23-133205","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["1.01","3.02","3.03","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Magenta to merge with Dianthus in reverse merger; Dianthus holders to own 78.7% of combined firm","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Dianthus stockholders will own ~78.7% of combined company; Magenta holders ~21.3%.","Concurrent $70M private placement of Dianthus shares and pre-funded warrants closing pre-merger.","Magenta holders get one CVR per share tied to net proceeds from legacy asset sales by Dec 31, 2023.","Magenta CEO and board largely replaced; 6 of 8 board members designated by Dianthus.","Termination fee of $13.3M payable by either party under specified conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299904,"accession_number":"0001193125-23-093153","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Magenta Therapeutics pays $14.8M to terminate Cambridge sublease with Novartis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time termination payment of $14,780,188 to Novartis for early exit from 69,000 sq ft sublease.","Sublease originally scheduled to end Feb 2028 or earlier; terminated effective March 31, 2023.","Principal executive offices moving to 300 Technology Square, Cambridge, MA.","Sublease covered R&D, laboratory, and office space at 100 Technology Square."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320004,"accession_number":"0001193125-23-088185","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Magenta Therapeutics adopts one-year stockholder rights plan to support strategic review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rights plan triggers at 10% beneficial ownership; each right entitles holder to purchase preferred stock units at $3.75.","Plan expires March 30, 2024; includes qualifying offer clause allowing 10% of stockholders to call special meeting.","Board previously announced comprehensive strategic review to maximize shareholder value; rights plan provides time for review.","No dead-hand, slow-hand, or similar features; Board can redeem rights for $0.001 per right until trigger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320003,"accession_number":"0001193125-23-026931","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","2.05","5.02"],"status":"ready","headline":"Magenta Therapeutics to cut ~84% of workforce, CEO Gardner departs; CFO Mahoney becomes President","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved restructuring plan reducing workforce by up to 56 positions (~84%), substantially complete by Feb 17, 2023.","Expected severance and related costs of approximately $5.4 million by end of February 2023.","CEO Jason Gardner, CTO David Nichols, CCO Caren Deardorf, CPO Kristen Stants, and SVP Shawn Rose to leave the company.","CFO/COO Stephen Mahoney named President; Gardner resigns from board effective Feb 7, 2023.","Preliminary cash, cash equivalents, and marketable securities of ~$112M as of Dec 31, 2022 (unaudited)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320002,"accession_number":"0001193125-23-022825","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-02-02T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Magenta Therapeutics halts all programs, explores strategic alternatives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Halts all development programs; will explore strategic alternatives including acquisition, merger, or business combination.","Received Nasdaq deficiency notice for common stock bid price below $1.00 for 30 consecutive trading days.","Has 180 days (until July 31, 2023) to regain compliance with minimum bid price requirement.","No timetable set for strategic review; no assurance a transaction will be completed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320001,"accession_number":"0001193125-23-015154","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2023-01-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Magenta pauses MGTA-117 Phase 1/2 trial after participant death possibly related to drug","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Latest participant dosed at Cohort 3 level (0.08 mg/kg) experienced Grade 5 SAE: respiratory failure and cardiac arrest leading to death.","Death deemed possibly related to MGTA-117; reported to FDA as Suspected Unexpected Serious Adverse Reaction (SUSAR).","Magenta voluntarily paused dosing after consultation with the trial's safety Cohort Review Committee.","Trial is in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338169,"accession_number":"0001193125-22-308821","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Magenta stops MGTA-117 Cohort 4 dosing after two DLTs; to continue at Cohort 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Three participants dosed in Cohort 4 (0.13 mg/kg); two had dose-limiting toxicities (respiratory SAEs).","First DLT was Grade 4 respiratory SAE; second DLT triggered pre-specified stopping rules.","No DLTs observed in fifteen participants across first three cohorts.","Three of four Cohort 3 participants with paired samples showed cancer blast depletion in blood and bone marrow.","Magenta reported first DLT to FDA; plans to enroll more patients at Cohort 3 (0.08 mg/kg)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338168,"accession_number":"0001193125-22-303275","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"Magenta reports MGTA-117 Phase 1/2 data: no DLTs, two patients became transplant eligible","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MGTA-117 showed dose-dependent binding and depletion of CD117+ cells; no dose-limiting toxicities observed in 15 patients across Cohorts 1-3.","Two relapsed/refractory AML/MDS patients became eligible for transplant after a single dose of MGTA-117.","Phase 1/2 trial currently enrolling Cohort 4 (0.13 mg/kg); aggregate data including Cohort 4 expected Q1 2023.","Company plans to transition MGTA-117 into transplant-eligible AML/MDS patients in H1 2023 pending regulatory alignment.","MGTA-145 Phase 2 trial in sickle cell disease data now expected H1 2023 due to enrollment delays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338167,"accession_number":"0001193125-22-276477","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Magenta Therapeutics Q3 net loss $16.1M; cash $128.3M funds into Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $128.3M at Sept 30, 2022, down from $176.9M at Dec 31, 2021.","Net loss of $16.1M for Q3 2022 vs $17.4M in Q3 2021; R&D expense $11.2M, G&A $6.1M.","MGTA-117 Phase 1/2 trial in AML/MDS progressing; no related SAEs or DLTs; Cohort 3 enrollment completed.","CD45-ADC toxicology study done; IND-enabling ongoing; program update expected Dec 2022.","MGTA-145 sickle cell trial enrolling; initial data anticipated Dec 2022, comprehensive data H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":5242000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355540,"accession_number":"0001193125-22-222823","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-08-17T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Magenta Therapeutics appoints Michael Vasconcelles to board; CMO Jeffrey Humphrey departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Vasconcelles, M.D. appointed to board, filling vacancy from Alexis Borisy not being reelected.","Vasconcelles brings 30+ years in oncology; served as CMO at Flatiron Health and Unum Therapeutics.","Chief Medical Officer Jeffrey Humphrey parted ways on August 15, 2022, not due to disagreement.","Shawn Rose, M.D., Ph.D., appointed SVP and Head of Clinical Development effective immediately.","Rose joined Magenta in February 2022; previously at Annexon, Janssen, and Bristol Myers Squibb."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355539,"accession_number":"0001193125-22-211873","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Magenta Q2 net loss $17.3M; cash $139.4M; MGTA-117 interim data expected Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $139.4M as of June 30, 2022; funds operations into Q2 2024.","Net loss of $17.3M in Q2 2022 vs. $16.9M in Q2 2021; R&D expenses $11.6M, G&A $6.5M.","MGTA-117 Phase 1/2 trial progressing; interim clinical data from multiple dose cohorts on track for Q4 2022.","CD45-ADC IND-enabling studies ongoing; in-life toxicology complete; program update expected Q4 2022.","MGTA-145 stem cell mobilization trial in sickle cell disease initiated; initial data anticipated Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373730,"accession_number":"0001193125-22-186149","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Magenta Therapeutics elects Daniel and Ronneberg as Class I directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Thomas O. Daniel, M.D. received 29,064,311 votes for and 7,962,396 withheld.","Amy Lynn Ronneberg received 27,364,344 votes for and 9,662,363 withheld.","Ratification of KPMG as auditor passed with 52,877,344 for, 249,235 against.","Broker non-votes totaled 16,120,189 on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373729,"accession_number":"0001193125-22-151011","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Magenta Q1 net loss $23M; MGTA-117 shows target binding and rapid clearance at lowest dose","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.0M for Q1 2022 vs. $17.5M in Q1 2021; R&D expenses rose to $16.5M from $11.7M.","Cash, equivalents and marketable securities $156.6M as of Mar 31, 2022; expected to fund operations into Q2 2024.","Phase 1/2 MGTA-117 Cohort 1 data: target binding on CD117+ cells, rapid drug clearance within 48 hours, no serious drug-related AEs; dose escalation to Cohort 2 (0.04 mg/kg) underway.","One patient with low blast burden showed ~83% reduction of bone marrow blasts at day 14; supports planned transition to transplant-eligible AML patients.","IND-enabling studies for CD45-ADC ongoing; key toxicology results expected 2H 2022. MGTA-145 sickle cell trial startup progressing; initial data expected 2H 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373728,"accession_number":"0001193125-22-136748","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-05-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Magenta Therapeutics enters amended employment agreements with two executives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Thomas Beetham (CLO) base salary $435,000, target incentive 40% of base, amended severance details.","David Nichols (CTO) base salary $362,000, target incentive 40% of base, amended severance details.","Severance: 0.75x base plus pro-rata target outside change in control; 1x base plus 100% target and accelerated vesting within change in control period.","Agreements effective May 2, 2022, supersede prior employment agreements.","Standard COBRA subsidies included; subject to release and noncompetition covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373727,"accession_number":"0001193125-22-105004","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-04-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Magenta Therapeutics prioritizes MGTA-117, cuts workforce 14%, extends cash runway into Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MGTA-117 Phase 1/2 trial shows encouraging early data: well-tolerated with no significant adverse events, early pharmacodynamic signals.","Company reduces workforce by 14% and extends cash runway into Q2 2024 through spending prioritization.","Magenta to disclose summary of clinical observations from initial MGTA-117 patients in Q1 2022 earnings release in early May.","De-prioritizing other portfolio investments, pausing MGTA-145 dosing optimization trial in healthy subjects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392411,"accession_number":"0001193125-22-068757","cik":1690585,"company_name":"Dianthus Therapeutics, Inc. /DE/","ticker":"DNTH","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Magenta Therapeutics reports Q4 2021 net loss $19.3M; first patient dosed in MGTA-117 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities at Dec 31, 2021: $176.9M, expected to fund operations into Q4 2023.","First patient dosed and completed initial safety assessment in Phase 1/2 trial of MGTA-117 targeted conditioning; data expected in 2022.","IND-enabling studies initiated for CD45-ADC; dose-ranging toxicology results anticipated in H2 2022.","MGTA-145 stem cell mobilization program advancing in sickle cell disease; data expected in H2 2022.","Net loss of $19.3M for Q4 2021 vs. $18.2M in Q4 2020; R&D expenses increased to $13.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":4819921666.853929,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-08T23:59:59+00:00|392411"}